BioLife Solutions Details 2024 Executive Equity Awards Ahead of Virtual AGM

TL;DR

**BLFS's 2024 executive equity awards are a mixed bag of small numbers, suggesting either minimal new grants or a highly complex, low-value structure that warrants deeper investigation before the August 20th AGM.**

AI Summary

BioLife Solutions Inc. (BLFS) filed its DEF 14A on July 8, 2025, for the fiscal year ended December 31, 2024. The filing indicates a focus on executive compensation and governance, with specific data points for equity awards granted to both PEO and Non-PEO NEO members. For the period of January 1, 2024, to December 31, 2024, the fair value of equity awards granted to PEO members was $1, while for Non-PEO NEO members it was $2. The year-end fair value of outstanding and unvested equity awards granted in the covered year for PEO members was $3, and for Non-PEO NEO members it was $1. The vesting date fair value of equity awards granted and vested in the covered year for PEO members was $2, and for Non-PEO NEO members it was $3. Changes in fair value of outstanding and unvested equity awards granted in prior years for PEO members were $1, and for Non-PEO NEO members were $2. The change in fair value as of vesting date of prior year equity awards vested in the covered year for PEO members was $3, and for Non-PEO NEO members was $1. The company is holding its 2025 Annual Meeting of Stockholders virtually on August 20, 2025, at 9:00 a.m. Pacific Time.

Why It Matters

This DEF 14A filing provides crucial transparency into BioLife Solutions' executive compensation structure, specifically regarding equity awards for 2024. Investors can scrutinize these figures to assess alignment between executive incentives and shareholder value, especially given the specific dollar amounts for PEO and Non-PEO NEO members. Understanding these compensation details is vital for governance-focused investors and can influence perceptions of management's commitment to long-term performance. In the competitive electromedical and electrotherapeutic apparatus sector, attracting and retaining top talent through competitive compensation, while managing costs, is a key strategic challenge.

Risk Assessment

Risk Level: medium — The risk level is medium due to the extremely low and seemingly symbolic dollar values reported for executive equity awards (e.g., $1 for PEO equity awards granted in 2024). This could indicate either a reporting anomaly, a highly complex compensation structure not fully transparent in these summary figures, or a significant shift in compensation strategy that requires further explanation. Such ambiguity can lead to investor uncertainty regarding executive incentives and governance.

Analyst Insight

Investors should scrutinize the full proxy statement for detailed explanations of the reported executive equity award values, particularly the low dollar amounts, and prepare questions for the August 20, 2025, virtual Annual Meeting. A deeper dive into the compensation committee's rationale and the complete compensation tables is essential to understand the true incentive structure.

Key Numbers

• $1 — Fair value of equity awards granted to PEO members (For the period January 1, 2024 - December 31, 2024)
• $2 — Fair value of equity awards granted to Non-PEO NEO members (For the period January 1, 2024 - December 31, 2024)
• $3 — Year-end fair value of outstanding and unvested equity awards for PEO members (Granted in the covered year, January 1, 2024 - December 31, 2024)
• $1 — Year-end fair value of outstanding and unvested equity awards for Non-PEO NEO members (Granted in the covered year, January 1, 2024 - December 31, 2024)
• $2 — Vesting date fair value of equity awards granted and vested for PEO members (In the covered year, January 1, 2024 - December 31, 2024)
• $3 — Vesting date fair value of equity awards granted and vested for Non-PEO NEO members (In the covered year, January 1, 2024 - December 31, 2024)
• $1 — Change in fair value of outstanding and unvested equity awards for PEO members (Granted in prior years, January 1, 2024 - December 31, 2024)
• $2 — Change in fair value of outstanding and unvested equity awards for Non-PEO NEO members (Granted in prior years, January 1, 2024 - December 31, 2024)
• $3 — Change in fair value as of vesting date of prior year equity awards vested for PEO members (In the covered year, January 1, 2024 - December 31, 2024)
• $1 — Change in fair value as of vesting date of prior year equity awards vested for Non-PEO NEO members (In the covered year, January 1, 2024 - December 31, 2024)

Key Players & Entities

• BIOLIFE SOLUTIONS INC (company) — Registrant for DEF 14A filing
• SEC (regulator) — Recipient of DEF 14A filing
• August 20, 2025 (date) — Date of the 2025 Annual Meeting of Stockholders
• 9:00 a.m. Pacific Time (time) — Start time of the 2025 Annual Meeting of Stockholders
• PEO (person) — Principal Executive Officer compensation category
• Non-PEO NEO (person) — Non-Principal Executive Officer Named Executive Officer compensation category
• 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021 (address) — Business and Mail Address of BioLife Solutions Inc.
• 425-401-1400 (phone_number) — Business phone number of BioLife Solutions Inc.
• December 31, 2024 (date) — Conformed Period of Report end date
• July 8, 2025 (date) — Filing date of the DEF 14A

FAQ

Industry Context

BioLife Solutions Inc. operates in the electromedical and electrotherapeutic apparatus industry, a sector focused on medical devices and technologies. This industry is characterized by rapid innovation, stringent regulatory oversight, and a growing demand for advanced healthcare solutions, particularly in areas like cell and gene therapy which BioLife Solutions supports.

Regulatory Implications

As a publicly traded company in the medical technology sector, BioLife Solutions Inc. is subject to SEC regulations for its filings, such as the DEF 14A, ensuring transparency in executive compensation and corporate governance. Compliance with industry-specific regulations for medical devices is also critical for its operations and product offerings.

What Investors Should Do

1. Review the detailed executive compensation breakdown in the DEF 14A.
2. Note the dates and details of the 2025 Annual Meeting of Stockholders.

Key Dates

• 2025-08-20: 2025 Annual Meeting of Stockholders — This is the date for the company's annual meeting where key governance matters, including the election of directors and executive compensation, are voted upon by shareholders. The virtual format allows for broader participation.
• 2025-07-08: Filing of DEF 14A — This filing provides detailed information on executive compensation, governance, and matters to be voted on at the Annual Meeting, offering transparency to investors.

Glossary

DEF 14A

A Definitive Proxy Statement filed with the SEC, providing detailed information about matters to be voted on at a company's annual meeting, including executive compensation and director elections. (This is the primary document analyzed, containing crucial information about executive compensation and governance for BioLife Solutions Inc.)

PEO Member

Principal Executive Officer member, referring to the top executive(s) of the company. (Used to categorize compensation and equity awards for the highest-ranking executive(s) in the compensation tables.)

Non-PEO NEO Member

Non-Principal Executive Officer Named Executive Officer member, referring to other key executives of the company who are named in the proxy statement. (Used to categorize compensation and equity awards for other key executives besides the PEO.)

Equity Awards

Awards of company stock or stock options granted to employees, typically as part of their compensation package. (The DEF 14A filing details the fair value of equity awards granted, vested, and outstanding for the company's Named Executive Officers.)

Fair Value

The estimated market price of an asset or liability, often determined using valuation models for financial instruments like stock options. (Key metric used in the DEF 14A to quantify the value of equity awards granted to executives.)

Year-Over-Year Comparison

The provided DEF 14A filing for July 8, 2025, focuses heavily on executive compensation and governance for the fiscal year ended December 31, 2024. Specific financial performance metrics like revenue growth, net income, or margin changes compared to the previous year are not detailed within the provided summary of the DEF 14A. The filing highlights the fair value of equity awards granted and outstanding for PEO and Non-PEO NEO members, with values ranging from $1 to $3 across different award categories.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on July 8, 2025 by PEO regarding BIOLIFE SOLUTIONS INC (BLFS).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR